DV
Dividend Vision

CING — Cingulate Inc

Cingulate Inc (CING)

Total return is -99.5% over the past 4.7 years, 175.9 points behind SPY at 76.4%. Its deepest 1-year drawdown was 69.1%.

Cingulate Inc. is a biopharmaceutical company developing pharmaceutical products using its proprietary drug delivery platform technology for the treatment of ADHD and anxiety. The company's lead product candidate, CTx-1301 (dexmethylphenidate), is currently in Phase 3 clinical trials for ADHD in children, adolescents, and adults, while it also develops CTx-2103 (buspirone) for anxiety treatment and plans to initiate clinical trials for CTx-1302 (dextroamphetamine). The company does not currently distribute dividends, making it oriented toward investors seeking growth potential rather than current income.

CING key facts

Asset type
Stock
Asset class
Equity
Inception date
12/08/2021
Last close
$5.09
Market cap
$61,149,424
Average volume
207600.0
Beta
-0.915
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.33